{"product_id":"cort-ansoff-analysis","title":"(CORT) Corcept Therapeutics Incorporated ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Corcept Therapeutics Incorporated Ansoff Matrix Analysis gives a concise, company-specific view of growth options across market penetration, market development, product development, and diversification. The page contains a real preview\/sample of the analysis so you can judge style and substance before buying — purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKorlym in diagnosed endogenous Cushing’s syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKorlym is still Corcept Therapeutics Incorporated’s only commercial product, so market penetration centers on taking more share from the existing U.S. diagnosed endogenous Cushing’s syndrome pool. The goal is to reach more adult patients already diagnosed and eligible for medical therapy, where each added prescription directly expands Korlym’s base. That makes sales force reach, specialist awareness, and patient access the main levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHyperglycemia-linked patient targeting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKorlym targets a narrow pool: patients with hypercortisolism-linked hyperglycemia, often alongside type 2 diabetes or glucose intolerance. Corcept’s 2024 net revenue was about $640 million, showing this focused niche can still scale; in market penetration, the play is to win more of this clearly defined prescription set by concentrating on high-need patients and prescribers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-surgical and post-surgical cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated’s label covers adults whose surgery failed or is not an option, so this is its cleanest market-penetration play. It targets the chronic cortisol-control segment, where patients still need long-term medical therapy after surgery or instead of it. In a rare disease with low diagnosed volumes, even small share gains in this niche can move revenue fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOnce-daily oral treatment profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKorlym is a once-daily oral tablet, so Corcept Therapeutics Incorporated can sell convenience in a chronic endocrine market where long-term adherence matters. In 2025, Corcept Therapeutics Incorporated reported revenue of about $579 million, and this simple dosing profile helps support repeat use in Cushing syndrome care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnce-daily oral use supports adherence\u003c\/li\u003e\n\u003cli\u003eFits chronic specialty treatment routines\u003c\/li\u003e\n\u003cli\u003eHighlights convenience vs complex options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat matters because many endocrine regimens need dose changes and close monitoring, so a tablet taken once a day is easier to position in routine practice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. specialty prescriber concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorcept’s U.S. market-penetration play is tightly focused on endocrinologists and other specialty prescribers already treating Cushing’s syndrome, which keeps the sales effort on the highest-conviction channel. Cushing’s syndrome affects about 40,000 to 70,000 people in the U.S., so deeper share depends more on prescriber concentration than broad promotion. That makes each new specialist account high value without changing the product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on endocrinology-first prescribing.\u003c\/li\u003e\n\u003cli\u003eTarget rare-disease specialists only.\u003c\/li\u003e\n\u003cli\u003eGrow share inside a 40,000-70,000 patient base.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorcept’s Growth Hinges on Expanding Its Cushing’s Patient Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated’s market penetration is built on deeper share in the U.S. Cushing’s syndrome niche, where Korlym is its only commercial product. With 2025 revenue of about $579 million, growth depends on reaching more diagnosed adults, especially through endocrinologists, because the addressable U.S. pool is only about 40,000 to 70,000 patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$579 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. patient pool\u003c\/td\u003e\n\u003ctd\u003e40,000 to 70,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial product\u003c\/td\u003e\n\u003ctd\u003eKorlym\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Corcept Therapeutics Incorporated’s growth strategy through market penetration, market development, product development, and diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Corcept Therapeutics Ansoff Matrix snapshot to quickly align growth strategy and reduce expansion-planning guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, clinical, and financial sources to validate Ansoff-derived growth paths for Corcept, enabling quick verification and defensible strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader U.S. referral capture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated can widen Korlym access beyond core endocrinology prescribers by moving into more referral pathways and tertiary-care sites where Cushing’s syndrome is often diagnosed late. In 2024, Corcept Therapeutics Incorporated reported about $675 million in total revenue, showing the size of the current base. Because Cushing’s is still underdiagnosed, each new center can lift patient capture without changing the drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity diabetes clinic awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated can use community diabetes clinic awareness as an adjacent market because Korlym treats hyperglycemia secondary to endogenous Cushing’s syndrome, a rare disease affecting about 40 to 70 people per million. Diabetes clinics see many patients with type 2 diabetes or glucose intolerance, so they can help find cases that are often missed.\u003c\/p\u003e\n\u003cp\u003eThe drug does not change; the prescriber base does. That makes referral education in diabetes settings a low-friction market development move for Corcept Therapeutics Incorporated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-surgical follow-up populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCorcept’s approved adult group includes patients whose surgery failed or was not an option, opening a post-surgical follow-up market for persistent hypercortisolism. This lets the Company sell into endocrine centers that keep treating residual disease after procedures, not just newly diagnosed cases. It also broadens repeat-care demand, since unresolved Cushing’s syndrome often needs long-term medical management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUnderserved U.S. geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorcept Therapeutics can extend Korlym across underserved U.S. regions by widening access where specialty endocrine care is thin. This is a geographic reach play, not a new-product launch, because the brand already has national U.S. market coverage. The upside comes from faster diagnosis, stronger referral links, and better payer and clinic access in lower-density markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting Korlym brand\u003c\/li\u003e\n\u003cli\u003eNational U.S. market\u003c\/li\u003e\n\u003cli\u003eFocus on weak endocrine access\u003c\/li\u003e\n\u003cli\u003eGeographic reach, not product change\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty pharmacy and chronic care channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKorlym is a chronic once-daily oral therapy, so Corcept Therapeutics Incorporated can sell it through specialty pharmacy and refill channels instead of only hospital starts. That fits the big unmet pool of diagnosed but untreated patients, especially in Cushing syndrome, where care is often delayed for years.\u003c\/p\u003e\n\u003cp\u003eMarket development here means widening access points, not changing the product. One line: more chronic-care channel reach can turn diagnosis into ongoing therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFits long-term outpatient use.\u003c\/li\u003e\n\u003cli\u003eReaches diagnosed, untreated patients.\u003c\/li\u003e\n\u003cli\u003eSupports specialty pharmacy distribution.\u003c\/li\u003e\n\u003cli\u003eImproves refill and persistence flow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorcept’s growth hinges on broader Cushing’s diagnosis and referral reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket development for Corcept Therapeutics Incorporated is about pushing Korlym into more diagnosis and referral points, not changing the drug. With about $675 million in 2024 revenue and Cushing’s affecting roughly 40 to 70 per million people, even small gains in specialty, diabetes, and regional care access can raise patient capture.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$675 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCushing’s prevalence\u003c\/td\u003e\n\u003ctd\u003e40-70 per million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eCorcept Therapeutics Incorporated Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelacorilant for Cushing’s syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRelacorilant is Corcept Therapeutics Incorporated's lead Cushing’s syndrome drug and a clear product-development step because it extends the same cortisol biology behind Korlym into a new therapy. In 2025, Corcept kept it in late-stage development, aiming to broaden its endocrine franchise after Korlym already built a $675 million-plus revenue base. That gives the move strong fit with the existing market and lower launch risk than a new disease area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelacorilant plus nab-paclitaxel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated advanced relacorilant plus nab-paclitaxel in advanced ovarian tumors through Phase II, making it a clear follow-on from the same cortisol-modulation platform. In Ansoff terms, this is product development: a new use for an existing mechanism, not a new market. The Phase II readout supports pipeline depth and lowers single-asset risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelect cortisol modulators for mCRPC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated is using selective cortisol modulators for metastatic castration-resistant prostate cancer (mCRPC) as a next-product move inside oncology. It takes the company’s cortisol science into a new cancer setting, where mCRPC remains a high-need, established market with limited durable treatment options. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSelect cortisol modulators for antipsychotic weight gain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated is using selective cortisol modulators for antipsychotic-induced weight gain, which is a clear product development move into a separate metabolic side-effect market. This broadens the pipeline beyond Korlym’s Cushing’s syndrome base and could open a larger patient pool if later-stage data keep showing weight and metabolic benefit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets antipsychotic-related weight gain\u003c\/li\u003e\n\u003cli\u003eBuilds a new metabolic use case\u003c\/li\u003e\n\u003cli\u003eReduces reliance on Korlym alone\u003c\/li\u003e\n\u003cli\u003eExpands the pipeline, not just the label\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFKBP5 gene expression assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated is adding FKBP5 gene expression assays to its pipeline, which pushes its Product Development strategy toward biomarker-led testing. That fits its cortisol focus by pairing drug research with a more targeted way to measure pathway activity in patients.\u003c\/p\u003e\n\u003cp\u003eIt can help Corcept link diagnosis, monitoring, and future companion-use testing for cortisol-related care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiomarker-based assay concept\u003c\/li\u003e\n\u003cli\u003eSupports targeted cortisol testing\u003c\/li\u003e\n\u003cli\u003eExtends pipeline beyond therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorcept Extends Its Cortisol Platform Beyond Korlym\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated is using product development to extend its cortisol platform beyond Korlym, with relacorilant driving late-stage Cushing’s work, ovarian cancer Phase II testing, mCRPC, and antipsychotic-induced weight gain. Korlym already supports a $675 million-plus revenue base, so these moves build on an existing market and lower launch risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelacorilant\u003c\/td\u003e\n\u003ctd\u003eLate-stage\u003c\/td\u003e\n\u003ctd\u003eNew therapy, same biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOvarian cancer\u003c\/td\u003e\n\u003ctd\u003ePhase II\u003c\/td\u003e\n\u003ctd\u003ePlatform expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emCRPC, weight gain\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003eNew uses, same science\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology entry through ovarian tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRelacorilant plus nab-paclitaxel moves Corcept Therapeutics Incorporated into ovarian cancer, a new disease market and a new product concept, so it is diversification. The Phase 3 ROSELLA study targets platinum-resistant ovarian cancer, a setting with high unmet need and limited options. This move expands Corcept beyond its Cushing's syndrome franchise, which drove $618.7 million in 2024 revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProstate cancer cortisol biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSelective cortisol modulators for metastatic castration-resistant prostate cancer move Corcept Therapeutics Incorporated into a new oncology segment, far beyond Korlym’s Cushing’s syndrome base. Prostate cancer is the second most common cancer in men, with about 1.5 million new cases and 397,000 deaths globally in 2022. That makes this a clear diversification play: new product, new market, new commercial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePsychiatry-linked metabolic disorder market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAntipsychotic-induced weight gain sits in a neuropsychiatric-metabolic market outside Corcept Therapeutics Incorporated's current Cushing’s and oncology base. A selective cortisol modulator for this use would add a new patient pool, with antipsychotics used in over 20 million U.S. prescriptions a year, and a new prescriber base in psychiatry. That is clear diversification across both product and market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiagnostic biomarker business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFKBP5 gene-expression assays can open a non-drug revenue stream, so Corcept Therapeutics Incorporated moves from pure pharma into diagnostics. That is a true diversification play: diagnostics sit in a different market, with different buyers, pricing, and reimbursement, than therapeutic sales. One clean example: if a test helps match patients to therapy, Corcept can earn from both drug and diagnostic economics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-drug revenue path\u003c\/li\u003e\n\u003cli\u003eSeparate market from drugs\u003c\/li\u003e\n\u003cli\u003eDirect diversification beyond therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCortisol-platform expansion beyond Cushing’s\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCorcept’s cortisol platform is its broadest diversification move: it uses one biology engine to chase metabolic, oncology, and neuropsychiatric markets beyond Cushing’s. That matters because a single platform can create several addressable diseases, not just one niche, and Corcept already reports a pipeline across these areas, including relacorilant in oncology and other cortisol-linked programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne science base, multiple markets\u003c\/li\u003e\n\u003cli\u003eMoves beyond Cushing’s\u003c\/li\u003e\n\u003cli\u003eSpans metabolic, cancer, neuropsychiatric care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorcept Expands Beyond Cushing’s Into Oncology and Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCorcept Therapeutics Incorporated’s diversification is real because it is moving from Cushing’s syndrome into oncology, psychiatry, and diagnostics. Relacorilant in ROSELLA targets platinum-resistant ovarian cancer, while the prostate cancer and weight-gain programs open new prescriber bases and payer models. Corcept Therapeutics Incorporated reported $618.7 million revenue in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eType\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelacorilant\u003c\/td\u003e\n\u003ctd\u003eNew market\u003c\/td\u003e\n\u003ctd\u003eOvarian cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProstate program\u003c\/td\u003e\n\u003ctd\u003eNew market\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFKBP5 test\u003c\/td\u003e\n\u003ctd\u003eNew product\u003c\/td\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234241487113,"sku":"cort-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/cort-ansoff-matrix.webp?v=1785715565","url":"https:\/\/dcfanalyst.com\/products\/cort-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}